Synergistic Hypolipidemic and Immunomodulatory Activity of Lactobacillus and Spirulina platensis

Hyperlipidemia is a significant risk factor for atherosclerosis and coronary heart disease (CHD). The aim of this study was to investigate hypolipidemic effects of Lactobacillus, Spirulina and their combination on Swiss albino mice fed a regular or high-cholesterol diet. Rosuvastatin was used as a reference drug The highest body weight, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol LDL-C and the lowest high-density lipoprotein cholesterol were recorded in a positive control group (G5). Treatment with Lactobacillus or Spirulina or by their combination resulted in a significant decrease in body weight, TC, TG, LDL-C and significant increase in HDL-C (p < 0.05) in both mice fed a regular diet or high-cholesterol diet. The treatments induced a significant increase in Hb, MCHC and HCT levels in mice fed a regular diet (p < 0.05). They did not induce a significant effect on these parameters in mice fed a high-cholesterol diet, while treatment with standard rosuvastatin induced a significant decrease in these parameters (p < 0.05). The treatments induced a significant increase in the platelet count and WBC number in mice fed a regular diet p < 0.05), while they induced significant decrease in these parameters in mice fed a high-cholesterol diet p < 0.05. They also stimulated the innate immunity represented by both monocyte and neutrophil cells in mice fed a regular diet, while this immunity was reduced in mice fed a high-cholesterol diet. It also caused a marked reduction in inflammation and an improvement in the congestion of cardiac tissues, the aorta, and the spleen. The treatment of hyperlipidemic mice with combination of Lactobacillus and Spirulina gave similar results to those obtained with treatment by rosuvastatin.